Monte Rosa Therapeutics (GLUE) Non-Current Assets (2020 - 2026)

Monte Rosa Therapeutics' Non-Current Assets history runs 7 years deep, the most recent figure standing at $58.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 3.35% year-over-year to $58.9 million; the TTM figure through Mar 2026 stood at $232.5 million (down 7.85% YoY), while the FY2025 annual figure was $55.5 million, down 9.49% from the prior year.
• Non-Current Assets was $58.9 million for Q1 2026 at Monte Rosa Therapeutics, up from $55.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $70.5 million in Q2 2023 to a low of $25.6 million in Q1 2022.
• Historically, Non-Current Assets has averaged $61.8 million across 5 years, with a median of $63.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets soared 538.48% in 2022, then dropped 10.03% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $66.5 million in 2022, then gained by 1.56% to $67.5 million in 2023, then dropped by 9.25% to $61.3 million in 2024, then retreated by 9.49% to $55.5 million in 2025, then advanced by 6.14% to $58.9 million in 2026.
• The last three Non-Current Assets figures came in at $58.9 million (Q1 2026), $55.5 million (Q4 2025), and $58.0 million (Q3 2025), per Business Quant data.